Ask AI
ProCE Banner Activity

Highlighting HIV Prevention: Pivotal Studies Presented EACS and ID Week 2025

Clinical Thought

From coadministration of contraceptives and gender-affirming hormone therapy and PrEP persistence, to real-world implementation and cost breakthroughs, new insights from IDWeek and EACS show why expanding choice and access to emerging PrEP options matters now more than ever to Africa.

Released: November 21, 2025

Review Activity

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare

Target Audience

This activity is intended for physicians, pharmacists, registered nurses, and other healthcare professionals who care for people living with or at risk of HIV infection.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Devise HIV management strategies based on the results of recent clinical studies of established antiretroviral agents

  • Integrate the latest scientific findings to develop and optimize effective HIV prevention interventions

Disclosure

Primary Author

Kenneth Ngure, MPH, MSc, PhD, has no relevant financial relationships to disclose.